Business Description
Aridis Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US0403341045
Description
Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.
Financial Strength
| Name | Current | Vs Industry | Vs History |
|---|
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 90.22 | |||||
9-Day RSI | 77.6 | |||||
14-Day RSI | 68 | |||||
3-1 Month Momentum % | 725 | |||||
6-1 Month Momentum % | 725 | |||||
12-1 Month Momentum % | 1550 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
FCF Margin % | -91.28 | |||||
OCF Margin % | -91.03 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -5.45 | |||||
EV-to-Forward-EBIT | 35.48 | |||||
EV-to-EBITDA | -8.39 | |||||
EV-to-Forward-EBITDA | 7.79 | |||||
EV-to-Revenue | 0.25 | |||||
EV-to-Forward-Revenue | 1.07 | |||||
EV-to-FCF | -0.27 | |||||
Earnings Yield (Greenblatt) % | -18.35 | |||||
FCF Yield % | -13383.58 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:ARDS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aridis Pharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 19.647 | ||
| EPS (TTM) ($) | -0.162 | ||
| Beta | -248.1706 | ||
| 3-Year Sharpe Ratio | 0.72 | ||
| 3-Year Sortino Ratio | 5.26 | ||
| Volatility % | 1495.13 | ||
| 14-Day RSI | 68 | ||
| 14-Day ATR ($) | 0.000489 | ||
| 20-Day SMA ($) | 0.00109 | ||
| 12-1 Month Momentum % | 1550 | ||
| 52-Week Range ($) | 0.0001 - 0.05 | ||
| Shares Outstanding (Mil) | 44.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aridis Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aridis Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 141 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 50 days | ||
| Annual report for 2025 | 2026-06-29 | In 4 days | ||
| First quarter earnings results for 2026 | 2026-06-29 | In 4 days | ||
| General meeting for 2025 | 2026-06-23 | 0.00 (+0.00%) |
Show
Entries
Aridis Pharmaceuticals Inc Frequently Asked Questions
What is Aridis Pharmaceuticals Inc(ARDS)'s stock price today?
The current price of ARDS is $0.00. The 52 week high of ARDS is $0.05 and 52 week low is $0.00.
When is next earnings date of Aridis Pharmaceuticals Inc(ARDS)?
The next earnings date of Aridis Pharmaceuticals Inc(ARDS) is 2026-06-29 Est..
Does Aridis Pharmaceuticals Inc(ARDS) pay dividends? If so, how much?
Aridis Pharmaceuticals Inc(ARDS) does not pay dividend.
Guru Commentaries on OTCPK:ARDS
No articles.
Press Release
Articles on Aridis Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers